Panel identifies mutations for targeted therapy in melanoma, like BRAF, NRAS, KIT.
Some mutations that occur in BRAF during melanoma progression are actionable targets for therapeutic agents. Testing for the BRAF V600 somatic mutations (V600E and V600K) in metastatic melanoma tumour tissue may assist in determining which patients will likely benefit from anti-BRAF therapeutics and, if a V600 mutation is present, whether they will be eligible for accessing the anti-BRAF agent dabrafenib under the Pharmaceutical Benefits Scheme (PBS).
Melanoma Gene Panel
Testing of malignant melanoma tissue to determine eligibility for access to dabrafenib or vemurafenib under the PBS
BRAF, NRAS, KIT
MassARRAY
1 week from receipt of slides
73336 – Criteria apply
If not MBS eligible, please contact 1800 822 999 for pricing details
Pathologist determinable. Internal request form or standard pathology request form.
FFPE Tumour Tissue
6 x 5 micron slides plus 1 x H&E stained slide required
